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1. Introduction 
1.1 A brief history of basic cancer research driven target discovery  
The incidence of cancer has risen dramatically over the last century due to the improved 
treatments of chronic diseases and as a consequence of an ever aging population that results 
in elevated cancer development(Hanahan and Weinberg 2000). As a result of the dramatic 
rise in cancer incidence significant efforts have been placed on developing new strategies for 
the improved diagnosis and the treatment of cancer. Traditionally, ionizing radiation 
and/or cytotoxic chemotherapies like platinum derivatives and anti-metabolites have been 
most widely used as anti-cancer treatments and although these agents can still have 
significant effects on improving longevity in patients, the toxicity of these agents along with 
high frequency of acquired resistance requires the development of more specific anti-cancer 
agents.  
International research efforts over the past thirty years have revolutionized our 
understanding of cancer developments. Pioneering distillation of this knowledge has led to 
the development of “the hallmarks of cancer” that specifies specific pathway perturbations 
in the development of the disease(Hanahan and Weinberg 2000). These rate-limiting stages 
are comprised of numerous biological systems that need to be perturbed during the multi-
step evolution of the full cancer cell. The key systems maintaining tissue integrity and which 
are perturbed in cancer development include pathways that mediate genome instability, 
inflammation, sustained cell proliferation, evasion of tumour suppressor signals, death 
resistance, immortality, angiogenesis, metastasis, immune system silencing, and energy 
metabolism (Table 1). 
This research knowledge summarized above has been acquired using a range of approaches 
including the study of cancer causing animal viruses like SV40 or human oncogenic viruses 
like HPV, the use of “model” organisms like bacteria, yeast, worms, and flies that 
recapitulate apoptosis and cell cycle concepts, and the development of human cancer cell 
lines that mimic certain aspects of cancers. Despite this enormous knowledge of cancer 
mechanisms, there have been relatively few anti-cancer drugs developed for routine clinical 
use from such information. In fact, the most “targetted” and common anti-cancer agents are 
those that either exploit knowledge of the physiology of cancer (like the anti-estrogen 
Tamoxifen) (Easton, Pooley et al. 2007) or those that exploit the use of natural products like  
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Table 1. 
Taxol (that targets microtubules and effects cell division)(Cowden and Paterson 1997). This 
is not to say that there are no novel agents being developed from our vast knowledge of 
cancer mechanisms; a large panel of small molecules have indeed been developed that 
target specific protein kinases, acetyltransferases, proteases, protein-folding enzymes, and 
other pro-oncogenic enzymes. Some of these small molecules form at the least proof-of-
concepts in cancer models for the drug-ability of classes of enzyme: (i) cell cycle enzymes 
such as CDK1/2 are targeted by a small molecule named Roscovitine(Meijer, Borgne et al. 
1997; Kim, Alarcon et al. 2009; Rule 2011); (ii) the protein folding enzyme HSP90 is targeted 
by the anti-tumour anti-biotic Geldanamycin (Kim, Alarcon et al. 2009); (iii) the protease 
component of the proteasome is targetted by a small peptide-mimetic Velcade (Rule 2011); 
(iv) a pro-apoptotic protein-protein interaction is mimicked by the tetra-peptide mimetic 
SMAC(Wang, Lu et al. 2011); (v) the E3 ubiquitin ligase MDM2 is targetted by a peptide 
mimetic named Nutlin(Vassilev, Vu et al. 2004); and (vi) histone de-acetylases are targeted 
by small molecules named Sirtuins(Medda, Russell et al. 2009). Although the majority of 
such drug-leads are not in the clinic, many of these pro-oncogenic enzymes will likely form 
important targeted therapies in the future. However, there is also some thought that the 
small molecule “landscape” that can be exploited to develop specific anti-cancer drugs has 
been relatively exhausted and that the new frontier involving “biologics” will provide a 
more revolutionary approach for treating large populations in the long-term.  
2. The future of cancer therapeutics using clinical cancer models and 
biologics 
In addition to the classic drug discovery process using small molecules that target enzyme 
pockets, the development of biologics, including the use of peptides, monoclonal antibodies, 
and aptamers, which has lagged the development of small anti-cancer molecules based on 
classic chemistry, will likely form a growing niche in the future. In part, this is due to the 
fact that the pharmaceutical industry has had one hundred years to develop the expertise of 
organic chemistry and has in a sense saturated the small molecule landscape. The 
exploitation of monoclonal antibodies that target extracellular receptors and/or peptide-
aptamers that target the more difficult protein-protein interaction is only approximately 20 
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years old. However, the use of biologics like monoclonal antibodies and to a lesser extent 
protein-protein interaction inhibitors is emerging as a major market leader in all cancer 
based therapeutics. There are currently 10 FDA approved monoclonal antibodies for the 
treatment of cancer (Table 2). 
 
Antibody Brand name Approval Type Target Indication 
Rituximab Rituxan 1997 Chimeric CD20 NHL 
Trasuzumab Herceptin 1998 Humanized ErbB2 Breast Cancer 
Gemtuzumab Mylotarg 2000 Humanized CD33 AML 
Alemtuzumab Campath 2001 Humanized CD52 CLL 
Ibritumomab 
tiuxetan 
Zevalin 2002 Murine CD20 NHL 
Tositumomab Bexxar 2003 Murine CD20 NHL 
Bevacizumab Avastin 2004 Humanized VEGF Colorectal cancer 
Cetuximab Erbitux 2004 Chimeric EGFR Colorectal cancer, Head 
and Neck cancer 
Panitumumab Vectibix 2006 Human EGFR Colorectal cancer 
Ofatumumab Arzerra 2009 Human CD20 CLL, NHL, DLBCL 
Table 2. FDA approved mAbs for cancer treatment. 
One of the largest sectors in the current pharmaceutical market is Oncology, which is largely 
due to the lack of targeted drugs for improved treatment of the vast number of different 
cancer types. Traditionally anti-cancer drugs fall into two loose categories either those 
which are cytotoxic (platinum based drugs) or those, which go after specific 
targets/proteins affecting a particular pathway. While traditionally the cytotoxic based 
chemotherapies have been most widely used there is now a need for the more targeted 
approach. Of these targeted therapies monoclonal antibodies (mAbs) are emerging as the 
market leaders in all cancer based therapeutics holding an 80% share of the US targeted 
cancer market (Aggarwal 2010) . Monoclonal based therapeutics have been around for the 
last 20 years with 30 immunoglobulins (IgGs) approved for a variety of conditions. One of 
the major limitations of monoclonal antibody therapeutics is target selection. While many 
companies first selected the clinically validated targets in the literature this area has become 
over crowded. Companies are now developing 2nd and 3rd generation antibodies towards 
these same targets either towards different epitopes, longer half-lives or with different 
scaffolds. (Beck, Wurch et al. 2010). However, the academic research and medical 
community has a key role to play in the target discovery process. This will greatly increase 
the pool of targets with which the pharmaceutical industry can exploit to begin to improve 
the costly process of developing novel anti-cancer treatments.  
2.1 Targeting oncogenic kinase receptors using mAbs 
Despite the fact that there are currently a paucity of well-defined, clinically accepted targets 
in oncology, a good example of a monoclonal antibody arising from physiologically relevant 
cancer model comes from the history of the development of the monoclonal that targets 
Her2, tratsuzumab (herceptin). Her2 was discovered as an ocogene activated by point 
mutations in chemically induced rat neroblastomas (Schechter, Stern et al. 1984). HER2 is a 
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type 1 transmembrane glycoprotein divided into three domains: an N-terminal extracellular 
domain (ECD), a single α-helix transmembrane domain (TM), and an intracellular tyrosine 
kinase domain. The extracellular domain forms a large structure capable of binding a ligand 
although no known ligand has yet been found for Her2. Although no ligand is known for 
Her2 it is known that its dimerization with the other Her family members is required for its 
activation by inducing auto-phosphorylation of its intracellular tyrosine kinase domain. 
From its inception in the early 80’s in rat neuroblastomas Her2 later went on to be shown to 
be overexpressed in a subset of breast cancers, with over-expression leading to poor 
prognosis (King, Kraus et al. 1985; Slamon, Clark et al. 1987). It was this association with 
overexpression and poor prognosis that led to the development of antibodies towards the 
extra-cellualar regions of these receptor tyrosine kinases. The resulting antibody named 
tratsuzumab was a humanized mouse monoclonal antibody and was later approved by the 
FDA in 1998 for treatment of metastatic breast cancer (Slamon, Leyland-Jones et al. 2001).  
 
 
Fig. 1. The Her2 Signalling pathway. HER signaling pathway in breast cancer. There are 
four membrane receptor tyrosine kinases involved in Her signaling (HER1[EGFR],HER2, 
HER3 and HER4) and a number of known ligands (epidermal growth factor 
[EGF],transforming growth factor a [TGFa] and heregulins [HRG]). Ligand binding induces 
conformational changes in the receptor allowing homo and hetero-dimerization 
transmitting signals via phosphorylation on intra-cellular domain activating PI3K/AKT, 
RAS/MEK/MAPK cascades. The monoclonal antibody trastuzumab targets the HER2 
receptor preventing it from dimerizing and activating its singaling pathways. 
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Tratsuzumab binds to a site close to the transmembrane region which is out with the 
potential ligand docking site effecting dimerization with other Her family members (Tai, 
Mahato et al. 2010). It was an instant success when used along side conventional 
chemotherapeutic agents with recurrence rates halved and mortality dropping by 30% 
which was seen to far out weigh the small risk of cardiotoxicity sometimes seen (Chang 
2007). Such data highlight the utility of identifying receptors as anti-cancer targets and 
mAbs in particular as tools with which to develop specific and effective anti-cancer agents. 
However, this history highlights the time scale involved in the process from target discovery 
to clinically approved use of an agent.  
2.2 Targeting hypoxic cells using mAbs 
Another example of a physiologically relevant cancer target that is proving to be important in 
oncology is Carbonic anhydrase-IX (Thiry, Dogne et al. 2006). One of the key hallmarks of 
cancers is the change in metabolism linked in part to lowered oxygen supply (Hanahan and 
Weinberg 2011). In human cancers, hypoxia develops from an inadequate supply of oxygen, 
which is primarily a physiological change in the tissue due to structurally disturbed 
microcirculation and reduction in O2 diffusion. Solid tumor growth is limited by 
vascularization and indeed promoted by angiogenesis, which is necessary for oxygen and 
nutrient supply. Hypoxia can induce the expression of many genes, including the key 
transcription factor HIF-1 that can in turn facilitate the induction of genes implicated in altered 
metabolism such as GLUT1/3 glucose importers and Carbonic Anhydrase IX (Figure 2).  
 
 
Fig. 2. Regulation of extracellular acidification and glycolysis in hypoxic cells. The 
transcription factor HIF-1a is degraded in normoxic cells through the VHL tumour 
suppressor protein. In response to lowered oxygen concentrations, HIF-1a is stabilized and 
forms a complex with HIF-lb to induce adaptive gene products. Some of these gene 
products include CA-IX and GLUT1/3 that coordinately mediate glycolysis and 
acidification that together drive survival in cancer cells. GLUT1/3 drives glucose transport 
where cellular energy is derived from glycolysis. CA-IX catalyzes extracellularly 
condensation of carbon dioxide and water to hydrogen ions and carbonate. Carbonate ions 
are transported intracellularly where CA-II neutralizes hydrogen ions and carbonate to 
carbon dioxide, which is transported from the cell.  
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The latter enzyme surprisingly functions as an intrinsic marker of cancer hypoxia and 
numerous mAbs and small molecule leads have been developed that target and exploit the 
hypoxia-specific nature of this isozyme. Many potent CA inhibitors derived from 
acetazolamide, ethoxzolamide and benzenesulfonamides have been shown to inhibit the 
growth of several tumor cell lines in vitro and in vivo(Vullo, Innocenti et al. 2005), although 
the specificity for isoforms and other enzymes like Aquaporin might add to the therapeutic 
responses. mAbs have also been developed independently to CA-IX and numerous studies 
have been developed showing that such mAbs can be used to target in vivo hypoxic regions 
of cancers (Zatovicova, Jelenska et al. 2010). Such mAbs might be used therapeutically as 
inhibitors of the enzyme or more possibly as carriers of cargo in a focussed attempt to 
increase local concentration of cyto-toxics.  
2.3 Exploiting the immune system using mAbs 
Immunological disorders have successfully been treated by targeting cytokines and 
associated receptors with a number of mAbs currently approved and many in clinical trials. 
A major imitation of most animal cancer models such as xenografts in immune 
compromised nude mice, not to mention the use of invertebrate model organisms or human 
cancer cell lines, is that the immune system is not taken into account as a variable factor. 
With so much known about the pathways involved in immunological conditions and so 
many mAbs in development and their success rate relatively high there is little need to 
identify new targets in this area. Cancer on the other hand is a different story due to its ever-
evolving state. Cancer arises from multiple mutations driving the proliferation and survival 
of the cell so to put the brakes on this requires hitting the right targets (Weiner, Surana et al. 
2010). Going for the validated targets provides a route from which companies can get to 
market quickly with their blockbuster drugs but this is getting increasingly harder. Until 
now many have steered away from discovering totally novel targets as this is more risky 
and the road to market is much longer, but the proteomic technology is now available and 
reliable to analyze clinical tissue and identify novel cancer targets. (Beck, Wurch et al. 2010)  
To date most targeted cancer therapies which have entered the clinic have done so by being 
used in combination with other cytotoxic agents. A good example of this is bevacizumab an 
anti-VEGF antibody, which alone showed no survival benefit but used in combination with 
oxaliplatin and 5-fluorouracil provided a two and a half month survival advantage in 
metastatic colon cancer (Kerbel 2006) . Cancer treatment is made even harder by the ability 
of cancer cells to overcome the toxicity of drugs by becoming resistant to the drug 
themselves. This ability has led many to people proposing the only way to treat cancer is via 
a drug combination strategy (Sawyers 2007). To achieve this goal we need to discover novel 
targets and develop new drugs which can be used in synergy or as second, third line 
treatments to combat the ever evolving mechanisms of cancer to evade treatment.  
2.4 BiTE therapy 
Bi-specific antibodies are also being explored in the treatment of some malignancies with the 
aim to engage the patients’ immune system to attack the tumor. The emerging leader in this 
field is blinataumomab, an anti CD19 and CD3 bi-specific single chain BiTE antibody 
(Bargou, Leo et al. 2008). With the knowledge that T cells are involved in the immune 
surveillance of cancer and their presence within tumors can effect the patients outcome, it is 
not surprising that exploiting T cells to control tumor growth is being explored (Swann and  
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Smyth 2007). Over the last 20 years many attempts have been made to achieve this such as 
vaccines, ex-vivo expanded T cells and T cell-activating antibodies, either alone or in 
combination with treatments such as IL2, IFN2a and GM-CSF to stimulate T cells (Nagorsen 
and Baeuerle 2011). These attempts thus far have yielded relatively low response rates 
presumably due to the nature of cancer to escape the pressure put on them by these 
treatments by losing molecules involved in T cell recognition for example. 
Bi-specific antibodies can overcome the ability of cancer to evade such treatments by passing 
the need for a cancer cell to posses the ability to recognize T cells themselves. One arm of the 
the bi-specific antibody is targeted towards a surface antigen on cancer cells such as EGFR, 
Her2, or cell differentiation antigens such as CD20, CD22 or CD19. The second arm of the 
antibody is then targeted towards an activating component of the T cell such as CD3. The 
binding of both of these antigens brings together the cancer cells and T cells resulting in the 
activation of any cytotoxic T cells causing lysis of the tumor cells. The BiTE antibody 
blinatumomab is currently in clinical trials for use in NHL and ALL with promising results 
so far (Nagorsen and Baeuerle 2011).  
3. Novel cancer target discovery using proteomic approaches 
It is important to point out that many of the targets of monoclonal antibodies like those 
reviewed above were not discovered from basic cancer research using model organisms like 
yeast, worms, and flies, but were discovered from understanding using human cancer 
material the extracellular proteins driving cancer growth or resistance and exploiting 
knowledge of the immune system as a co-factor in cancer control. The development of 
“OMICS” platforms like transcriptomics and proteomics over the past ten years and the 
application of these OMICS approaches to human cancer tissue has revolutionized target 
discovery in the cancer field and has identified a large panel of novel anti-cancer targets that 
had not been previously realized. This highlights the need to develop approaches that can 
be used to interrogate clinical samples and place less emphasis on the use of model 
organisms like yeast, bacteria, and flies as doors to discover novel cancer targets. In fact, not 
only do such model organisms fail to model the ”hallmarks” of cancer like immunity and 
metastasis, they do not express many of the oncogenic targets that are proving to be 
important in human cancer. This in part is due to the gene explosion in the animal lineage 
that accompanies complex vertebrate life; such advanced life is linked to complex problems 
faced by vertebrates that include multi-functional organs as well as much longer life spans 
and an immune system to combat pathogens that could easily colonize the rich tissue 
niches. It is also due to the surprising loss of some cancer genes on the evolutionary path of 
flies and worms. For example, the p53 tumour suppressor and its co-factor MDM2 appeared 
together very early in animal evolution and it was surprising to learn that the model 
organisms like flies and worms have lost these 2 key genes(Lane, Cheok et al. 2010). Thus, 
although an advantage of using invertebrate model organisms is that genetic screens 
coupled to rapid life span can be used to identify growth regulatory targets, such organisms 
do not have many of the oncogenic targets that are important for human cancer. An example 
of vertebrate-specific cancer gene discovered since the OMICS revolution was a gene named 
Anterior-Gradient-2. This gene and its orthologue AGR3 evolved from a founding gene that 
is in invertebrates named ERP18. The AGR2/AGR3/ERP18 family has since been under 
strict evolutionary control with no subsequent gene amplification and diversification, 
suggesting that the function of this family of vertebrate-specific genes is highly integrated 
and fixed. AGR2 specifically (i.e. not AGR3 not ERP18) plays a fundamental role in limb 
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regeneration in amphibia, acts like a classic transforming oncogene, can mediate metastasis 
in animal models, and its expression can predict poor prognosis in various cancer 
types(Hrstka, Nenutil et al. 2010). Another important cancer gene that functions not only as 
a tumour suppressor but plays a key role in extending life span in mice, is a gene named 
ARF (p14 or p19 in human and mouse, respectively)(Maclaine and Hupp 2009). This gene 
interestingly is only in mammalian lineage and is one of the fastest adaptively evolving 
genes in mammals suggesting a key role in host-pathogen arms race that typifies genes 
under positive evolutionary pressure. There are other such cancer genes that are not present 
in classic invertebrate model organisms and highlights further the need for better clinical 
models to accurately understand the physiology of human cancer.  
The limitation on the use of clinical tissue to identify novel and/or potential anti-cancer 
protein targets stems form the paucity of well-characterized and well collected clinical 
samples. That is to say, the methods for protein identification in clinical tissue are adequate, 
but the development of useful clinical models lag the technological developments. 
Traditionally or originally, examinations of differentially expressed proteins have utilized 
“tumour” vs “normal” tissue and exploited differential protein expression methods to identify 
proteins “over-expressed” in tumour vs normal tissue. Such protein differential display 
techniques (now called proteomics) including 2-d gel electrophoresis linked to mass-
spectrometric fingerprinting has been available for almost twenty years. However, only with 
the full sequencing of human genome, software to annotate all potential open reading frames, 
and the use of MS/MS to sequence directly peptides and match peptides to the human 
proteome was relatively large scale proteomics screening useful. There are now many 
examples where differential protein expression can be quantitated in clinical tissue using mass 
spectrometric methods including iTRAQ(Collins, Lau et al. 2010) or label-free and data-
independent methods like PAcIFIC (Panchaud, Scherl et al. 2009). Historically, most MS/MS 
protein sequencing has been performed using reversed-phase liquid chromatography (HPLC) 
tandem mass spectrometry (MS/MS) approaches with data-dependent ion selection. This so-
called shotgun proteomics is combined with liquid or gas phase fractionation to increase 
coverage of the proteome, which is relatively speaking, still limiting. The recently described 
PAcIFIC has two advantages over these powerful, but traditional data-dependent shotgun 
proteomics approaches. First, because every m/z channel is evaluated systematically to 
collision induced dissociation (CID) there is an increase in the dynamic range of proteins 
identified. This permits detection of a larger number of low abundant proteins, such as kinases 
and transcription factors, that may have relatively weak precursor ions available for detection. 
Second, because of the thorough nature of PAcIFIC, protein sequence coverage is dramatically 
improved which increases confidence in protein identification, that is another contentious 
topic in the proteomics fields. Another generic limitation of full proteome coverage is in part 
due to biological issues like the fact that buffers used for lysis cannot extract all cellular 
proteins. Thus cutting edge proteomics approaches using mass spectrometry aim to elevate the 
coverage of proteins sequenced in a biological sample.  
In addition to the strength and limitations of protein sequencing methods from biological 
tissue, it is also becoming apparent that examination of proteins differentially expressed in 
cancer versus normal tissue is not specifying adequate target-discovery. Many studies have 
compared cancer vs normal tissue in discovering differentially expressed proteins, but these 
data sets do not identify specific drivers of the disease because the tissues are very different 
from each other. More thoughtful approaches and study designs are required to identify 
higher-confidence anti-cancer drug targets that involve progression models where disease 
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zones have evolved from precursor tissue regions. Some examples of such clinical 
proteomics approaches will be described below. 
3.1 Discovering novel p53 regulators using clinical proteomics 
Cancer development is a multi-step process which involves clonal evolution of cells under 
natural selection resulting in the survival of cells with an enhanced capacity to evade normal 
growth control (Rajagopalan, Bardelli et al. 2002). The core genetic blueprint of the cancer 
cell is being developed and involves universal perturbation in sets of signal transduction 
pathways regulated by well-studied proteins such as RAS, p16, and p53 (Hanahan and 
Weinberg 2000). Of these many pathways, one of the most frequently mutated and silenced 
genes in human cancers is p53 (Vousden and Lane 2007). The tumour suppressor protein 
p53 is a stress-activated transcription factor that mediates cellular response to a diverse 
range of environmental signals including DNA damage, virus infection, and metabolic 
stress (Levine, Hu et al. 2006) (Hupp and Walkinshaw 2007). The most widely studied p53 
inhibitor, the MDM2 oncogene, is often over-produced in a range of cancers resulting in 
attenuation of the p53 response (Levine, Hu et al. 2006) (Arva, Gopen et al. 2005).  
 
 
Fig. 3. Model describing stage and tissue-specific mutation of the p53 gene in cancer 
progression. Tissue morphology changes in the so-called cancer progression sequence has 
been categorized as metaplasia, dysplasia, adenoma, carcinoma, and metastasis. Key gene 
mutations occur at different stages in colorectal cancer and oesophageal cancer; colorectal 
cancer develops through mutations of APC in dysplasia, RAS in adenoma, and p53 in 
carcinoma. By contrast, oesophageal adenocarcinoma, that is linked in part to the DNA-
damaging effects of acid and bile reflux, progresses through p16 and p53 mutation in 
metaplasia and through to RAS mutation in carcinoma. The unusual feature of oesophageal 
cancer is the very early selection of the p53 gene mutation very early in “progression” and 
highlights a novel opportunity to understand the environment-gene-proteome interactions 
in disease. 
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However, there is a need to develop novel p53 inhibitory screens in vertebrates, if not in 
human cancers, in order to expand our knowledge of cancer-causing gene pathways and to 
identify the proteome of novel and uncharacterized targets.  
One approach to discover novel clinically relevant oncogenes that inhibit p53 would be to 
analyze key clinical tissue for gene products implicated in p53 silencing in human diseases 
using OMICs technologies; i.e. proteomics or transcriptomic methodologies. In order to 
identify potentially novel p53 inhibitors in clinical tissue, a clinical proteomics screen had 
previously been set up in a proliferative disease (Barrett’s epithelium) which is an 
intermediate in the development of oesophageal adenocarcinoma. The notable feature of 
Barrett’s epithelium is that selection pressures including acid and bile stresses are being 
placed on mutation of the p53 gene(Jankowski, Provenzale et al. 2002; Leedham, Preston et 
al. 2008) suggesting a relatively unique microenvironment for the identification of novel p53 
modifiers (Hupp 2000; Darragh, Hunter et al. 2006; Little, Nelson et al. 2007). It is under this 
unique microenvironment that potentially novel pro-oncogenes might be identified. 
Accordingly, the proteomics approach to identifying a range of proteins upregulated in this 
proliferative tissue using clinically derived material identified a protein named Anterior 
Gradient-2 (AGR2) which was validated as a potent inhibitor of p53-dependent 
transcription(Yagui-Beltran, Craig et al. 2001; Pohler, Craig et al. 2004). AGR2 was originally 
identified as a potential secretory protein that is highly expressed in Xenopus eggs (Aberger, 
Weidinger et al. 1998). Apart from its function as a p53 inhibitor (Pohler, Craig et al. 2004), 
subsequent studies have shown a significant role for AGR2 in a range of biological 
pathways including cell migration, cellular transformation, metastasis (Liu, Rudland et al. 
2005) (Wang, Hao et al. 2008), and limb regeneration in vertebrates (Kumar, Godwin et al. 
2007). Clinical studies have also implicated the protein in inflammatory bowel disease 
(Zheng, Rosenstiel et al. 2006), hormone-dependent breast cancers (Zweitzig, Smirnov et al. 
2007) (Mackay, Urruticoechea et al. 2007), and in predicting poor prognosis in prostate 
cancers (Zhang, Forootan et al. 2007). The molecular mechanisms underlying these wide-
ranging biological pathways triggered by AGR2 are still not defined and as the AGR2 gene 
is confined to vertebrates, the AGR2 gene pathway cannot be analyzed and solved directly 
in genetic systems like yeast, flies, or worms. However, it remains important to determine 
what the interacting proteins-or Interactome-of AGR2 is in order to understand its role in 
development and cancer. One of the published binding proteins for AGR2 is the 
extracellular receptor linked to metastasis, C4.4A, possibly providing a therapeutic target for 
mAbs validation in AGR2-positive cancers.  
3.2 Discovering novel Tamoxifen agonists using proteomics 
Tamoxifen is one of the first generation smart therapies that can give rise to substantial 
improvements in disease management. However, tamoxifen has agonistic effects involving 
either intrinsic resistance or acquired resistance. This would indicate that there are factors 
differentially expressed in patients that confer tamoxifen resistance or that there are 
differences in tamoxifen induced proteins in patients that confer cancer cell growth. A 
number of transcriptomics approaches have been used to identify genes that are induced or 
suppressed by Tamoxifen that identify key rate-limiting stages of pro-oncogenicity. One of 
the most striking observations in Tamoxifen resistance is the suppression of the immune 
system regulatory factor IRF-1 and highlights again the important but under-studied link 
between suppression of the immune system and cancer development. However tantalizing 
the later data might be, this work was performed using cell lines and there is very little 
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evaluation of Tamoxifen agonist targets using clinical tissue in conjunction with proteomics. 
The identification of proteins that are induced by Tamoxifen would identify potential 
targets for sensitization strategies. A very recent proteomics study was designed using 
clinical samples to search for differentially expressed proteins in tamoxifen resistant or 
tamoxifen-sensitive patients and identified a number of proteins that when expressed 
predict poor response, thus highlighting the power of proteome screens using well-defined 
clinical cancer samples to identify effector proteins of the disease (Umar, Kang et al. 2009).  
3.3 Discovering clinically relevant pro-metastatic targets using proteomics 
One of the key problems in cancer responses to treatment is not necessarily the initial 
response, but the relapsed or metastatic development. Thus, one approach to improve cancer 
treatments would be to not target an oncogene that is over-produced in cancers, but to target 
the proteins that have been specifically upregulated in the relapsed or invasive cancers. 
Although this is relatively difficult in all cancer types, it is possible in breast cancers where 
biopsies can be taken from original and invasive lymph node samples. The development of 
such clinical proteomics screens was recently published by Bouchal, Roumeliotis et al. 2009 
iTRAQ-2DLC-MS/MS proteomic analysis has been used to identify proteins overproduced in 
metastatic tissue vs relapsed primary tissue from the same patient. This study revealed 
potential new biomarkers and therapeutic targets in metastatic breast cancer tissue that would 
not be possible to predict form other research approaches. From this screen one of the most 
up-regulated trans-membrane proteins was identified as IFITM1.  
Interferon-induced transmembrane protein 1 (IFITM1), also known as 9–27, CD225, and 
Leu13, is a member of the interferon-induced transmembrane protein family. Its major role 
is as a component of a membrane complex that transduces antiproliferative and homotypic 
adhesion signals in lymphocytes (Lewin, Reid et al. 1991; Sato, Miller et al. 1997). The CD19 
cell surface receptor complex regulates B lymphocyte development and function and is 
composed of at least four proteins; CD19, CD21 (CR2, complement receptor 2), CD81 
(TSPAN-28) and IFITM1 (Sato, Miller et al. 1997). Aside from its physiological role it has 
been shown to promote cancer progression by enhancing cell migration and invasion in 
head and neck cancer and gastric cancer (Yang, Lee et al. 2005; Hatano, Kudo et al. 2008). 
IFITM1 knockdown has also been shown to inhibit proliferation, migration and invasion of 
glioma cells (Yu, Ng et al. 2010). Therapeutic monoclonal antibodies have been developed 
targeting the CD19 protein and have show efficacy in chronic lymphocyte leukemia (CLL) 
and related CD19(+) B-cell malignancies (Awan, Lapalombella et al. 2009). Since IFITM1 has 
been shown to form a receptor complex with CD19, targeting it with monoclonal antibodies 
could also prove beneficial. 
3.4 Novel mAb therapeutics in cancer 
Another example of a more sophisticated approaches using a combination of proteomics for 
target discovery in cancer tissue to novel mAb therapeutics stems from the pioneering work 
of Dario Neri’s laboratory. Conventional chemotherapeutics work by targeting highly 
proliferating tissues such as cancer but also target those normal tissues which also 
proliferate such as endothelial cells. The idea that antibodies can target cancer tissues alone 
relies on identifying a target that is only expressed in the tumor or at very least at a 
threshold that wouldn’t have massive side effects in normal tissue. A popular approach to 
identify such targets is to evaluate the differential expression of proteins in cancerous vs 
normal tissues but finding the appropriate technique which will give the most accurate 
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results is difficult. Once method developed by Dario Neri is the biotinylation of proteins, 
this involves the in vivo perfusion of tumor baring animals or ex vivo perfusion of 
surgically resected human organs with reactive ester derivatives of biotin. The resulting 
biotinylated proteins can then be easily recovered using streptavidin followed by on-resin 
proteolyitic digestion and HPLC and finally mass spectrometry to identify proteins 
assessable in the circulatory system. This technique led to the identification of BST-2 as a 
novel target for antibody-based therapy (Schliemann, Roesli et al. 2010). Numerous 
proteomic techniques have been used over the years to discover new targets such as a phage 
display protocol where by mice are injected with a phage library and tissues excised and 
phage bound are identified (Pasqualini and Ruoslahti 1996). Direct analysis of tumor vs. non 
tumor vasculature via perfusion with colloidal silica beads (Jacobson, Schnitzer et al. 1992; 
Durr, Yu et al. 2004; Oh, Li et al. 2004). Finally a method of biotinylating proteins on the 
surface of endothelial cells or in the vasculature extra cellular matrix and subsequent 
proteomic analysis (Rybak, Ettorre et al. 2005; Roesli, Neri et al. 2006). Since tumors are 
continually proliferating they have a high demand for oxygen so require a very extensive 
vasculature system to supply their need. Targeting the tumor vasculature is an attractive 
approach to treat cancer and this technique has led to the identification of numerous 
potential targets present in tumor vasculature over normal vasculature.  
Targeting the tumor neo-vasculature has been demonstrated by developing antibodies 
towards the EDA domain of fibronectin. This alternatively spliced extra-domain B (EDB) of 
fibronectin is one of the best characterized markers of angiogenesis and is essentially absent 
in all normal adult human tissue but is strongly expressed in the vasculature of most 
aggressive tumor types. Antibodies to this target have been shown to selectively localize to 
the tumor neo-vasculature in animal models and patients with cancer (Villa, Trachsel et al. 
2008). Although these antibodies are not therapeutic themselves they are being used as 
carriers for other potent anti-tumor agents such as I131, IL2 , interferon-α and TNF.  
The ability to deliver cytokines, growth factors and other immunomodulators specifically to 
the tumor is a great advance in targeted therapeutics. Interferon-α is currently used in the 
clinic to treat some cancer types and exerts its anticancer effects either by direct action on the 
tumor or by indirect mechanisms effecting the patients immune system. The direct anti-
tumor effects involve the inhibition of tumor cell proliferation, down regulation of 
oncogenes, up regulation of tumor suppressors and avtivating proapoptotic pathways. The 
immunostimulatory effects of interferon-α play a part in the indirect anticancer properties of 
interferon-α (Frey, Zivanovic et al. 2011). Interferon-α was the fisrt cytokine to to become 
approved for clinical use in 1986 in hairy cell leukemia and is widely used today for 
treatment of malignancies such as hepatitis c and metastatic melanoma and in combination 
with some anticancer drugs. One of the major limitations of interferon-α use is its short half-
life and potent toxicity limiting the ability to increase dose. Using an antibody targeting the 
tumor vasculature and tagging it with interferon-α allows for specific tumor targeting with 
the cytokine, avoiding healthy tissue and without the high doses and subsequent toxicity of 
conventional interferon-α treatment. This potential new treatment could help further 
enhance current cancer treatments strategies (Frey, Zivanovic et al. 2011). The conjugation of 
bio-active agents such as IL-2 is a promising area in cancer treatment. There has been great 
success in conjugating the cytokine IL-2 to antibodies with an EDB-IL2 (L19-IL2) antibody 
currently in stage II clinical trials. L19-IL2 also shows high efficacy in lymphoma models 
active both as a monotherapy and very potent when used in combination with the anti-
CD20 mAb rituximab (Schliemann, Palumbo et al. 2009). 
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4. Summary 
The history of cancer research has shown us that highly inventive and innovative 
approaches like the use of model organisms such as bacteria to study fundamental 
mechanisms of DNA repair, the use of worms to study programmed cell death, and the use 
of yeast to study the cell cycle has identified fundamental hallmarks of cancers (Hanahan 
and Weinberg 2011). However, the by-pass of the immune system in human cancer 
development and the realization that many cancer genes are only expressed in vertebrates 
has placed more pressure on developing more physiological models to identify anti-cancer 
drug targets. We have reviewed here some of the key targets identified from exploiting our 
knowledge of the human physiology of cancer, the use of monoclonal therapeutics as a 
growing innovation in cancer treatment, and the use of mass spectrometry in conjunction 
with clinical approaches to develop more physiological therapeutic strategies. 
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